Romeyer Dherbey Jordan, Bertels Frederic
Microbial Population Biology, Max Planck Institute for Evolutionary Biology, August-Thienemann-Straße 2, Plön, Schleswig-Holstein 24306, Germany.
Virus Evol. 2024 Jan 13;10(1):veae007. doi: 10.1093/ve/veae007. eCollection 2024.
With the emergence of widespread antibiotic resistance, phages are an appealing alternative to antibiotics in the fight against multidrug-resistant bacteria. Over the past few years, many phages have been isolated from various environments to treat bacterial pathogens. While isolating novel phages for treatment has had some success for compassionate use, developing novel phages into a general therapeutic will require considerable time and financial resource investments. These investments may be less significant for well-established phage model systems. The knowledge acquired from decades of research on their structure, life cycle, and evolution ensures safe application and efficient handling. However, one major downside of the established phage model systems is their inability to infect pathogenic bacteria. This problem is not insurmountable; phage host range can be extended through genetic engineering or evolution experiments. In the future, breeding model phages to infect pathogens could provide a new avenue to develop phage therapeutic agents.
随着广泛的抗生素耐药性的出现,噬菌体在对抗多重耐药细菌方面是一种有吸引力的抗生素替代品。在过去几年中,许多噬菌体已从各种环境中分离出来用于治疗细菌病原体。虽然分离用于治疗的新型噬菌体在同情用药方面取得了一些成功,但将新型噬菌体开发成一种通用疗法需要大量的时间和资金投入。对于成熟的噬菌体模型系统来说,这些投入可能不那么重要。从对其结构、生命周期和进化的数十年研究中获得的知识确保了安全应用和高效处理。然而,成熟的噬菌体模型系统的一个主要缺点是它们无法感染致病细菌。这个问题并非无法克服;噬菌体宿主范围可以通过基因工程或进化实验来扩展。未来,培育能够感染病原体的模型噬菌体可能为开发噬菌体治疗剂提供一条新途径。